Clinical Trial Update: MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) [Phase 2]

View source ↗

Summary

Phase 2 trial of MK0974 (Telcagepant) for migraine prophylaxis in episodic migraine; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• MK0974

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Migraine | Phase 2 | Status: TERMINATED | Results posted: 2014-09-08